Adzynma Drug Information

ADZYNMA is indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).

Preparation and Administration

Use aseptic technique (clean and germ-free) throughout the procedure. Check the expiration date of the product prior to use. Do not use ADZYNMA if the expiration date has passed.

Reconstitution 1. Prepare a clean, germ-free, flat surface and gather all the materials you will need for the reconstitution and infusion. Figure A depicts the materials provided in the carton box.

Figure A 2. Use ADZYNMA within 3 hours after reconstitution and keep at room temperature not to exceed 86°F/30°C. Do not store at any other temperature.

Discard any unused reconstituted product if not used within 3 hours after reconstitution. 3. Allow the vials of ADZYNMA and diluent to reach room temperature before use. If the patient needs more than one vial of ADZYNMA per injection, reconstitute each vial according to the instructions stated under ‘Reconstitution’.

Inspect the reconstituted ADZYNMA solution for particulate matter and discoloration prior to administration. The solution should be clear and colorless in appearance. Do not administer if particulate matter or discoloration is observed. 4.

Wash and dry your hands thoroughly, and put on clean exam gloves. 5. Remove plastic caps from the ADZYNMA and diluent vials and place the vials on a flat surface ( Figure B ). Figure B 6.

Wipe the rubber stoppers with an alcohol swab and allow them to dry prior to use ( Figure C ). Figure C 7. Open the BAXJECT II Hi-Flow device package by peeling away the lid, without touching the inside ( Figure D ).

Do not remove the BAXJECT II Hi-Flow device from the package. Do not touch the clear plastic spike. Figure D 8.

Turn the package with the BAXJECT II Hi-Flow device upside down and place it over the top of the diluent vial. Press straight down until the clear plastic spike pierces through the diluent vial stopper ( Figure E ). Figure E 9.

Grip the BAXJECT II Hi-Flow device package at its edge and pull the package off the device ( Figure F ). Do not touch the exposed purple plastic spike. Figure F 10.

Turn the system over so that the diluent vial is now on top. Press the BAXJECT II Hi-Flow device straight down until the purple plastic spike pierces through the ADZYNMA powder vial stopper ( Figure G ). The vacuum will draw the diluent into the ADZYNMA powder vial.

You may notice some bubbles or foam – this is normal and should soon disappear. Wait until foam or bubbles dissipate before administration. Figure G 11.

Swirl the connected vials gently and continuously until the powder is completely dissolved ( Figure H ). Do not shake the vial. Figure H 12.

Visually inspect the reconstituted solution for particulate matter before administration. Do not use the product if particulate matter or discoloration is observed. 13. If the dose requires more than one vial of ADZYNMA, repeat step 1 to step 12 to reconstitute each vial.

Use a different BAXJECT II Hi-Flow device to reconstitute each vial of ADZYNMA and diluent. Administration Instructions 14. Take off the blue cap from the BAXJECT II Hi-Flow device ( Figure I ).

Attach a Luer-lock syringe ( Figure J ). Do not inject air into the system. Figure I Figure J 15.

Turn the system upside down (ADZYNMA vial is now on top). Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Figure K ). Do not administer ADZYNMA in the same tubing or container at the same time with other medicinal products for infusion.

Figure K 16. If a patient is to receive more than one vial of ADZYNMA, the contents of multiple vials can be drawn into the same syringe. Repeat this process for all reconstituted vials of ADZYNMA until the total volume to be administered is reached. 17.

Disconnect the syringe and attach a suitable injection needle or an infusion set. 18. Point the needle up and remove any air bubbles by gently tapping the syringe with your finger and slowly and carefully pushing air out of the syringe and needle. 19. Apply a tourniquet and clean the chosen infusion site with an alcohol swab ( Figure L ).

Figure L 20. Insert the needle into the vein and remove the tourniquet. 21. Infuse the reconstituted ADZYNMA slowly, at a rate of 2 to 4 mL per minute ( Figure M ).

A syringe pump may be used to control the rate of administration. Figure M 22. Take the needle out of the vein, place a cotton ball or gauze on the infusion site, and apply pressure for several minutes to stop bleeding.

Do not recap the needle. 23. Place the needle, syringe, and empty vials in a puncture-resistant sharps container. Do not dispose of syringes and needles in the regular waste.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety profile of ADZYNMA was evaluated in one, prospective, randomized, active-controlled, open-label, multicenter, two-period crossover study (Study 1) that treated 48 patients who had been previously exposed to ADAMTS13 through plasma-based products. Patients received ADZYNMA at the dose of 40 IU/kg/dose.

The adverse drug reactions (ADR) are listed in Table 2. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. Blood and lymphatic system: Neutralizing antibodies to ADAMTS13 with serious outcomes including death.

Pregnancy Risk Summary The safety of ADZYNMA for use during pregnancy has not been established in controlled clinical trials. Limited data with ADZYNMA use during pregnancy are insufficient to inform a drug-associated risk of adverse developmental outcomes. In determining whether ADZYNMA should be used in pregnancy, healthcare providers should balance the potential benefits with the potential risks.

The background rate of major birth defects and miscarriage in the indicated population is unknown. In the U.S. general population, the estimated background rate of major birth defects and miscarriage in clinically recognized pregnancies is respectively. Data Human Data There have been four cTTP patients exposed to ADZYNMA during pregnancy.

Two patients in a long-term extension study were found to be pregnant early in the first trimester while receiving prophylaxis with ADZYNMA. Both patients were discontinued from the study to comply with the protocol requirements. The first patient had no further exposure to ADZYNMA and had a first trimester miscarriage approximately two months after study discontinuation.

The investigator assessed the event was unrelated to ADZYNMA. The second patient resumed treatment with ADZYNMA under a compassionate use program and delivered a healthy full-term baby with no safety concerns reported by the investigator. Two additional cTTP patients were treated with ADZYNMA in a compassionate use program during pregnancy.

The first patient, in the third trimester of her second pregnancy, experienced a stroke and thrombocytopenia that was refractory to daily plasmapheresis. At 33 weeks of gestation, ADZYNMA treatment was started once weekly. ADAMTS13 activity levels normalized, thrombocytopenia resolved, and a healthy baby was delivered at 37 weeks with no safety concerns reported by the treating physician due to ADZYNMA.

The second patient had an exacerbation of her cTTP during her second trimester of pregnancy despite prior daily plasma exchange. Her pregnancy was considered to be at risk, with inadequate response to plasma-based therapies. ADZYNMA was started once weekly and induced clinical remission.

The baby was delivered by a cesarean section at week 29 and the treating physician reported no adverse events due to ADZYNMA. Whether ADZYNMA should be used in pregnancy is solely up to the medical judgment of the healthcare provider. Nonclinical Data In an embryo-fetal development study in rats, ADZYNMA was administered in female rats at 80, 200, or 400 IU/kg every third day from 2 weeks before mating through Day 16 of gestation and was not associated with any adverse maternal findings or treatment-related effects on embryo-fetal development.

There were no adverse maternal effects or findings in F1 or F2 offspring.

Pediatric Use The safety and effectiveness of ADZYNMA has been established in pediatric patients. Clinical trials included patients aged 2 years and older. Based on data from population pharmacokinetic (PK) analysis, no additional dose adjustments beyond body weight are required for this age group.

The recommended body-weight based dosing regimen in pediatric patients is the same as that in adults.

ADZYNMA is contraindicated in patients who have manifested life-threatening hypersensitivity reactions to ADZYNMA or its components. Do not use in patients who have manifested life-threatening hypersensitivity reactions to ADZYNMA or its components.